Iovance Biotherapeutics Inc
IOVAHealthcare|Biotechnology|USA
$4.23
-0.13 (-2.98%)
Tangible Book
$1.03
About
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Stock Price
+119.2%(1Y)
Pipeline Summary
34 total trials14
Phase 1
18
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 11Active: 6Completed: 9Withdrawn: 3NOT_YET_RECRUITING: 1AVAILABLE: 1Terminated: 3
Active Trials (17)
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904Metastatic Melanoma
Phase 3Recruiting
Enrollment: 670 participants
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT05483491Gastric Cancer
Phase 1Recruiting
Enrollment: 30 participants
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
NCT06566092Soft Tissue Sarcoma
Phase 1Active
Enrollment: 40 participants
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174Unresectable Melanoma
Phase 1Phase 2Recruiting
Enrollment: 53 participants
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
NCT05176470Locally Advanced Melanoma
Phase 1Active
Enrollment: 2 participants
BioScore
6.4/10
Watchlist
Ownership
Recent Insider Trades
Kirby Daniel GordonBUY
2025-06-0530,000 shares @ $1.84
Puri Raj K.BUY
2025-05-235,600 shares @ $1.74
Vogt Frederick GBUY
2025-05-1425,000 shares @ $1.69
Maynard Ryan DSELL
2024-11-1250,000 shares @ $10.06
Rothbaum Wayne P.BUY
2024-02-205,000,000 shares @ $9.15
Data last updated: Jul 13, 2026, 12:45 PM